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remarkable fidelity of the spliceosome in
defining exon-intron boundaries. Ling et
al. show that PTBP1 and PTBP2 help
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nonconserved cryptic exons. They also
find that titration of PTBP1 and PTBP2
splicing repression generates
transcriptome diversity required for
neuronal differentiation.
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The fidelity of RNA splicing is maintained by a net-
work of factors, but the molecular mechanisms that
govern this process have yet to be fully elucidated.
We previously found that TDP-43, an RNA-binding
protein implicated in neurodegenerative disease,
utilizes UG microsatellites to repress nonconserved
cryptic exons and prevent their incorporation into
mRNA. Here, we report that two well-characterized
splicing factors, polypyrimidine tract-binding protein
1 (PTBP1) and polypyrimidine tract-binding protein
2 (PTBP2), are also nonconserved cryptic exon re-
pressors. In contrast to TDP-43, PTBP1 and PTBP2
utilize CU microsatellites to repress both conserved
tissue-specific exons and nonconserved cryptic
exons. Analysis of these conserved splicing events
suggests that PTBP1 and PTBP2 repression is
titrated to generate the transcriptome diversity re-
quired for neuronal differentiation. We establish that
PTBP1 and PTBP2 are members of a family of cryptic
exon repressors.
INTRODUCTION
RNA splicing in higher eukaryotes is a complex but efficient pro-
cess that uses only170 spliceosomal factors (Wahl et al., 2009)
to reliably identify hundreds of thousands of exon and intron
boundaries with nucleotide precision (Chen and Manley, 2009;
Fu and Ares, 2014; Huelga et al., 2012). This delicate system is
often disrupted in human disease (Brinegar and Cooper, 2016;
Scotti and Swanson, 2016) and has been a major focal point for
interpreting mutations that are identified through whole-genome
medicine (Xiong et al., 2015). Currently, our ability to predict
exon-intron junctions from the primary genomic sequence is
limited, in part due to the loose consensus sequence of most
splicing proteins. Coupling next-generation sequencing technol-
ogywith a complete characterization of individual splicing factors104 Cell Reports 17, 104–113, September 27, 2016 ª 2016 The Auth
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Here, we report a model for the function of two well-studied
splicing factors, polypyrimidine tract-binding protein 1 (PTBP1)
and polypyrimidine tract-binding protein 2 (PTBP2) (Gil et al.,
1991; Markovtsov et al., 2000; Patton et al., 1991; Polydorides
et al., 2000).
PTBP1 (also known as PTB or hnRNP I) and its paralog, PTBP2
(also known as nPTB or brPTB), are RNA-binding proteins
that, in addition to roles involving mRNA regulation and gene
expression, have been extensively characterized as trans-acting
splicing repressors (Kafasla et al., 2012; Keppetipola et al., 2012;
Licatalosi et al., 2012; Xue et al., 2009). PTBP1 and PTBP2 both
utilize four highly conserved RNA-recognition motifs (RRMs) to
bind to their consensus sequences, the CU-rich pyrimidine
tract (Oberstrass et al., 2005). Interestingly, the expression pat-
terns of PTBP1 and PTBP2 are mutually exclusive, since
PTBP1 downregulates PTBP2 through an alternative splicing
event that leads to nonsense-mediated decay (NMD) (Boutz
et al., 2007). PTBP1 is highly expressed and PTBP2 is kept low
in most tissues except for certain organs such as brain, where
the opposite is true (Lilleva¨li et al., 2001). During neuronal differ-
entiation, PTBP1 is downregulated and PTBP2 is upregulated to
compensate (Li et al., 2014; Makeyev et al., 2007). Thus, it is
thought that PTBP2 controls an alternative splicing program
that is critical for neuronal maturation (Li et al., 2007; Raj and
Blencowe, 2015).
We recently found that TDP-43, a splicing factor implicated in
the pathogenesis of amyotrophic lateral sclerosis and frontotem-
poral dementia, binds to UG microsatellites to repress noncon-
served cryptic exons (Ling et al., 2015). TDP-43 loss of function
results in the incorporation of nonconserved cryptic exons that
often induce NMD of the associated mRNA. Since PTBP1 and
PTBP2 are splicing repressors that bind to CU repeats, we
reasoned that these two splicing factors might perform a similar
function.
We now report that PTBP1 and PTBP2 repress nonconserved
cryptic exons. Interestingly, while short pentamer pyrimidine
stretches have long been postulated to be a consensus binding
motif for PTBP1 (Ashiya and Grabowski, 1997; Pe´rez et al., 1997;
Xue et al., 2009), we find that highly repressed PTBP1/2 exonsor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
are flanked by long CU microsatellites (often >20 bp in length).
Furthermore, our analysis of unannotated splicing events reveals
a subset of conserved exons that, while repressed in undifferen-
tiated cells, become actively spliced in differentiated neurons.
Previous studies have characterized a PTBP1-specific alterna-
tive splicing program for early neuronal differentiation (Linares
et al., 2015) and a late program that is PTBP2 specific (Li et al.,
2014). The conserved exons identified in our work, however,
belong to the set of targets that are regulated by both PTBP1
and PTBP2. Our findings suggest a potential bridge between
the early and late programs via the titration of CU-repeat-associ-
ated splicing repression. Thus, PTBP1 and PTBP2 are precisely
coordinated to both repress deleterious nonconserved cryptic
exons and generate the alternative splicing complexity required
for differentiated tissue.
RESULTS
Recent studies have used high-throughput RNA-sequencing
(RNA-seq) technology to study the alternative splicing events
that are regulated by PTBP1 and PTBP2 (Gueroussov et al.,
2015; Li et al., 2014). To identify cryptic exons associated with
PTBP1 and PTBP2, we reanalyzed these published datasets
in addition to RNA-seq datasets generated from concurrent
knockdown of PTBP1 and PTBP2 in HeLa cells. As previously
described (Ling et al., 2015), unannotated splicing events were
identified in HEK293 (Gueroussov et al., 2015) and HeLa cells,
revealing numerous repressed exons within these PTBP1 and
PTBP2 knockdown datasets (Figures 1A and 1B; 183 total;
Data S1).
PTBP1/2 repressed exons could be classified as standard
cassette exons (Figure 1C), alternative splice site selections
leading to extensions of conserved exons (Figure 1D), or prema-
ture polyadenylation sites due to alternative 30 exon splicing (Fig-
ure 1E). The majority of repressed exons were cassette exons
(79%), while extensions (11%) and polyadenylation sites (10%)
contributed a smaller fraction (Figure 1F). Furthermore, 45%
of these human PTBP1/2 repressed exons resided in conserved
domains of the genome, while 55% were found in noncon-
served regions (Figure 1F). Indeed, many of the nonconserved
cryptic exons were predicted to introduce frameshifts or
stop codons (48%), which lead to NMD and the downregula-
tion of associated transcripts (Figure S1). Sequence analysis of
PTBP1/2 repressed exons further confirmed the presence of
adjacent CU microsatellites (Figure 1G). These microsatellites
reside in the canonical polypyrimidine tract of the 30 splice site,
although certain CU microsatellites are also found within the
repressed exon itself or downstream of the 50 splice site.
We then analyzed RNA-seq data from knockdown of either
PTBP1 or PTBP2 alone to verify that loss of both proteins is
required for conserved and nonconserved exon incorporation.
Due to compensation by PTBP2, many exons were still
repressed when only PTBP1 was reduced (Figure 2A). For
some exons, however, PTBP2 was not sufficient for complete
repression (Figures 2B and 2C). We also confirmed with immu-
noblot analysis that knockdown of PTBP1 alone led to increased
levels of PTBP2 (Figure 2D) and validated several repressed
exons by RT-PCR analysis (Figures 2E and 2F).To establish that repressed exons were direct targets of
PTBP1, we used the photoactivatable-ribonucleoside-enhanced
crosslinking and immunoprecipitation (PAR-CLIP) method to
map transcriptome-wide binding sites (Hafner et al., 2010). As
expected, intronic peaks corresponding to direct binding by
PTBP1 could be found adjacent to repressed exons (Figure S2).
Many reads also aligned to the more abundant exonic regions,
supporting the notion that PTBP1 has additional roles in mRNA
processing and translation (Kafasla et al., 2012; Keppetipola
et al., 2012). PAR-CLIP reads alsomapped PTBP1 to the alterna-
tively spliced exons of PKM and TPM2, which are sites that have
been previously identified as under the control of PTBP1 (David
et al., 2010; Xue et al., 2009). Numerous CU microsatellites can
be found directly upstream of these alternative exons, strength-
ening the model of CU-repeat associated splicing repression
(Figures 2G and 2H). Indeed, PTBP1 and PTBP2 may utilize
the CU microsatellite upstream of PKM exon 9 to regulate an
alternative splicing event that plays an important role in themeta-
bolism ofmany cancers (David et al., 2010; Israelsen et al., 2013).
Finally, to determine whether expression of PTBP1 could restore
exon repression, we also analyzed RNA-seq data obtained from
PTBP1/2 knockdown cells expressing full-length PTBP1 (Guer-
oussov et al., 2015) and observed that exons were again
repressed (Figures 2I and S3).
To validate that the nonconserved PTBP1/2 cryptic exons
identified in human cells were distinct from other species, we
examined RNA-seq data frommouse brain lacking Ptbp2 in neu-
rons (Li et al., 2014). Analysis of these datatsets revealed cryptic
exons that could be categorized as cassette exons (Figures 3A–
3C), exon extensions (Figures 3D and 3E), and polyadenylation
sites (Figures 3F and 3G) (166 total; Data S1). Furthermore,
robust CU microsatellites could be identified upstream, down-
stream, or internal to each cryptic exon (Figure 3H). As expected,
no overlap was found between human andmouse cryptic exons.
Intriguingly, the vast majority of unannotated exons identified
in the mouse neuron Ptbp2 knockout datasets were noncon-
served (91% inmouse comparedwith 55% in human) (Figure 3J).
Upon further analysis, we observed that the majority (63%) of
human conserved alternative exons—found to be repressed
in non-neuronal cells—are normally spliced in at high levels
in mouse neurons (Figures 4A–4C). Surprisingly, deletion of
Ptbp2 has either no impact on many of these neuron-included
exons (Figures 4B and S4) or only moderately increases exon in-
clusion (Figures 4C and S5). Alternative splicing analysis of the
mouse Ptbp2 knockout datasets fails to identify the importance
of these exons without the context of the human PTBP1 and
PTBP2 double knockdown.
What are the functional consequences of activating these
repressed exons during neuronal differentiation? Many of these
conserved sequences (54%) produce in-frame insertions that
may alter the protein structure to perform roles necessary for
neural development (Figure 4D; Table S1). In contrast, noncon-
served cryptic exons are generally not frame-preserving; only
3% of nonconserved cryptic exons are in-frame (Figure 4D).
Some conserved PTBP1/2 exons, however, appear to downre-
gulate non-neuronal transcripts through NMD (Table S2). For
example, SNAP23, a ubiquitous component of membrane fusion
machinery, appears to be downregulated by NMD as PTBP1/2Cell Reports 17, 104–113, September 27, 2016 105
Figure 1. Identification of Human Nonconserved Cryptic Exons and Conserved Tissue-Specific Exons Repressed by PTBP1 and PTBP2
(A and B) Analysis of RNA-seq data from concurrent knockdown of PTBP1 and PTBP2 in HEK293 (Gueroussov et al., 2015) and HeLa cells reveals unannotated
conserved (FERMT2, A) and nonconserved (ANKS6, B) repressed exons (green arrows).
(C–E) PTBP1/2 repressed exons can be classified as standard cassette exons (SPATA6, C), exon extensions (FLNA, D), and premature polyadenylation sites
(RUNX2, E).
(F) Approximately 45% of PTBP1/2 repressed exons are conserved, while 55% are nonconserved. The majority of exons are cassette exons (79%), while exon
extensions (11%) and polyadenylation sites (10%) constitute a smaller fraction.
(G) Repressed exons are flanked by CUmicrosatellites in the upstream, downstream, or internal sequence. Sequences that are missing the 30 splice site ‘‘AG’’ or
50 splice site ‘‘GU’’ dinucleotide reflect repressed exons that are premature poly(A) sites or exon extensions where a 50 or 30 splice junction is absent.
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Figure 2. Concurrent Knockdown of Both PTBP1 and PTBP2 Is Required for Cryptic Exon Activation
(A–C) RNA-seq data from control HeLa cells, double knockdown of PTBP1 and PTBP2 (red), single knockdown of PTBP1 (orange), and single knockdown of
PTBP2 (blue). While some repressed exons (green arrows) do not appear unless both PTBP1 and PTBP2 are knocked down (ANKS6, A), other exons are revealed
in single PTBP1 knockdown (FERMT2 and PHLDB2, B and C), supporting previous observations that PTBP2 may be a weaker repressor than PTBP1 in certain
contexts (Keppetipola et al., 2016; Markovtsov et al., 2000).
(D) Immunoblot analysis of PTBP1 and PTBP2 knockdown. PTBP2 levels increase after knockdown of PTBP1.
(E and F) Certain repressed exons are strongly spliced only after double knockdown of PTBP1 and PTBP2, while other exons (F) appear after single knockdown of
PTBP1, albeit at lower levels.
(legend continued on next page)
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repression decreases, allowing for the neuronal homolog
SNAP25 to dominate.
To explain these observations, we propose a splicing model
that builds upon the current mechanistic understanding of
PTBP1 and PTBP2 (Figure 5). In undifferentiated neural precur-
sor cells, PTBP1 expression is high, and both neuronal exons
and nonconserved cryptic exons are repressed. Through the
process of neuronal differentiation, PTBP1 expression is re-
duced and PTBP2 expression is increased, but because
PTBP2 is a weaker splicing repressor (Keppetipola et al.,
2016), neuronal exons become activated. Despite weaker
repression, however, PTBP2 is still able to repress deleterious
nonconserved cryptic exons. It is only under experimental condi-
tions that we are able to reduce PTBP1 and PTBP2 to levels low
enough for nonconserved cryptic exon activation. Thus, neurons
may titrate down the levels of PTBP1/2 repression to activate
conserved tissue-specific exons, thereby generating the tran-
scriptome diversity required for neuronal differentiation.
To further support this splicing model, we analyzed RNA-seq
data generated from the brain tissue of various vertebrate spe-
cies (Barbosa-Morais et al., 2012; Merkin et al., 2012). As ex-
pected, conserved exons that become activated during neuronal
differentiation are also present in brain tissues of other vertebrate
species (Figure S6). In contrast, nonconserved cryptic exons are
species specific and not found in any other vertebrate brains
(Figure S7). Finally, we also analyzed mouse RNA-seq data
from various tissue types to determine whether the splicing
of conserved exons was correlated with the expression of
PTBP1/2. Indeed, conserved PTBP1/2 exons were found in brain
and muscle—tissues that express low levels of PTBP1 (Lilleva¨li
et al., 2001; Llorian et al., 2016)—but not in colon, kidney, liver,
lung, spleen, or testes (Figure S8).
DISCUSSION
Our data establish that PTBP1 and PTBP2 are splicing factors
that utilize CU repeats to repress conserved tissue-specific
exons and nonconserved cryptic exons. These results expand
upon our previous finding that TDP-43 targets UG repeats to
repress nonconserved cryptic exons (Ling et al., 2015). In
contrast to TDP-43, however, PTBP1 and PTBP2 regulate both
conserved and nonconserved splicing events. This dichotomy
can be clearly demonstrated when repressed exons are func-
tionally categorized. For example, 54% of conserved exons are
in-frame, while only 3% of nonconserved cryptic exons are in-
frame, suggesting that conserved tissue-specific exons are far
more likely to alter protein sequences in a productive manner.
We also find that nonconserved cryptic exons, which only arise
after PTBP1/2 depletion, are completely repressed under normal
conditions across different tissue types and brains from various
vertebrate species. Indeed, the nonconserved cryptic exons
identified in brains of Ptbp2 knockout mice are not present in
any RNA-seq datasets from normal mouse or rat brain, despite(G and H) PTBP1 and PTBP2 have been previously identified to regulate alt
et al., 2010; Xue et al., 2009). Numerous CU microsatellites (yellow bars) c
(green arrows).
(I) Overexpression of full-length PTBP1 after double knockdown of PTBP1 and P
108 Cell Reports 17, 104–113, September 27, 2016high concordance betweenmouse and rat genomes. These find-
ings lead to the conclusion that conserved and nonconserved
exons are differentially regulated by PTBP1/2 and functionally
distinct.
We therefore propose the existence of a conserved versus
nonconserved axis of RNA splicing (Figure 6). Cells must
actively repress nonconserved cryptic exons that would other-
wise disrupt the fidelity of canonical mRNA splicing. In certain
contexts, however, activating conserved exons by reducing
repeat-associated repression may play an important role in
generating transcriptome and proteome complexity (Eom
et al., 2013). The conserved exons associated with PTBP1
and PTBP2 are expected to be important for neuronal differen-
tiation and may even play a role in muscle differentiation as well
(Figure S8). The mechanistic parallels among PTBP1, PTBP2,
and TDP-43 suggest that these splicing factors may belong
to a larger family of cryptic exon repressors. Given the diversity
of microsatellites sequences within the genome, we predict
that other cryptic exon repressors will be uncovered in the
near future.
Advances in whole-genome sequencing have greatly acceler-
ated in recent years, but our ability to interpret and understand
these vast amounts of data has lagged behind. This disparity is
particularly apparent when comparing exonic and intronic re-
gions of the genome. Mutations discovered in the exome reflect
direct changes in the encoded protein, but mutations that occur
in the intron have a far more mysterious effect. Intronic se-
quences that are regulated by cryptic exon repressors may
represent regions of susceptibility for neurodegeneration, can-
cer, and other conditions. Thus, characterizing the noncon-
served cryptic exons within the human genome may couple
with the advent of personalized genetic medicine and allow us
to more fully interpret SNPs and somatic mutations that arise
in human disease.EXPERIMENTAL PROCEDURES
Cell Culture and Manipulation
HeLa cells were cultured in DMEM (Corning, 10-017-CV) supplemented with
1% GlutaMAX (Thermo Fisher Scientific, 35050-061), 10% fetal bovine serum
(FBS; Corning, 35-010-CV), and 1% penicillin-streptomycin (Thermo Fisher
Scientific, 15070-063). Knockdown of PTB1 and PTB2 was performed by
transfecting using small interfering RNA (siRNA) as previously described
(Ling et al., 2015) (Sigma), while control was transfected with siRNA against
GFP (Thermo Fisher Scientific). Transfection of siRNA was achieved using
Lipofectamine 3000 (Thermo Fisher Scientific, L3000-008) following the
manufacturer’s protocol.
RT-PCR and qRT-PCR of Human Targets
cDNA was derived from transfected HeLa cell total RNA (1 mg total RNA/20 ml
first-strand cDNA reaction) using ProtoScript II (NEB, E6560S). Primers were
designed against cryptic exon targets, and PCR reactions were performed us-
ing Phusion High-Fidelity DNA Polymerase (New England Biolabs, M0530S).
qRT-PCR primers were designed against ANKS6, IQGAP1, LEPRE1, and
LEPREL2. Primers were then used to amplify cDNA products from controlsernatively spliced exons in genes such as PKM (G) and TPM2 (H) (David
an be seen directly upstream of upregulated alternatively spliced exons
TBP2 results in the restoration of exon repression (Gueroussov et al., 2015).
Figure 3. Identification of Mouse Nonconserved Cryptic Exons and Conserved Tissue-Specific Exons Repressed by Ptbp1 and Ptbp2
(A–G) Genetic deletion of Ptbp2 in mouse neurons (Li et al., 2014)—where Ptbp1 is already downregulated—reveals repressed exons that are analogous to those
found in humans. The identified exons can also be classified as cassette exons (Ryr3, Sympk, andMycbp2, A–C), exon extensions (Slc30a3 and Cacna1g, D and
E), and polyadenylations sites (Cdk7 and Wwp2, F and G).
(H) Robust CU microsatellites can be found in the upstream, downstream, or internal sequences. Sequences that are missing the 30 splice site ‘‘AG’’ or 50 splice
site ‘‘GU’’ dinucleotide reflect repressed exons that are premature poly(A) sites or exon extensions where a 50 or 30 splice junction is absent.
(legend continued on next page)
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Figure 4. Conserved PTBP1/2 Cryptic Exons Are Activated in Brain Tissue
(A–C) Conserved repressed exons identified in the human, non-neuronal RNA-seq datasets that are actively spliced in mouse neurons. Many of these activated
tissue-specific exons are surprisingly unaffected by Ptbp2 deletion (A and B; Figure S4) and would thus be undetected by alternative splicing software algorithms
when analyzing the mouse datasets without the context of the human double knockdown. Some exons, however, do show a moderate increase in splicing
frequency (C; Figure S5).
(D) When conserved and nonconserved exons are functionally categorized, a clear difference emerges. Conserved tissue-specific exons are more likely to
produce in-frame insertions into the protein sequence than nonconserved cryptic exons (54% versus 3%). In contrast, nonconserved cryptic exons are more
frequently not frame-preserving (i.e., NMD or premature polyadenylation).and PTBP1/2 knockdown, in triplicate, using the ABI Prism 7900 Sequence
Detector System.
Primer sequences used for RT-PCR and qRT-PCR are listed in Supple-
mental Experimental Procedures.
Photoactivatable-Ribonucleoside-Enhanced Crosslinking and
Immunoprecipitation of PTBP1
HeLa cells were transfected with a plasmid expressing PTBP1 tagged at the C
terminus with a dual 6His-biotin tag (Tagwerker et al., 2006). Cells were grown
for 14 hr in the presence of 4-thiouridine; media was then removed, and cells
were irradiated for 1 min with a 365-nm UV-LED light source (Hamamatsu, LC-
L5). Cross-linked cells were removed by scraping in PBS and then centrifuged,
and pellets were frozen at 80C. Pellets from ten 15-cm plates of cells were
resuspended in 7.5 ml 300 mM NaCl, 0.5% NP-40, 50 mM NaPO4 (pH 7.2),
10 mM imidazole, 6 M guanidine HCl, and protease inhibitor cocktail VII(I) The majority of exons are cassette exons (55%), while polyadenylation sites
extensions (33%) are found nearly three times higher in frequency.
(J) Furthermore, 91% of mouse repressed exons are nonconserved, while only 9%
of repressed exons are conserved. Cross-referencing the conserved human exon
led to the discovery that many (63%) of these exons are in fact actively spliced
110 Cell Reports 17, 104–113, September 27, 2016(RPI), and the fusion protein was purified by tandem affinity chromatography
and cross-linked RNA used for library construction and sequencing by Illumina
HiSeq as previously described (Schaughency et al., 2014).
For hexamer motif analysis, reads were deduplicated using the FASTX-
toolkit (Hannon Lab, Cold Spring Harbor Laboratory). Both deduplicated
and original reads were, then, aligned to the human genome (hg19) using
bowtie (v1.1.2) (Langmead et al., 2009) with the following options: -y–best–
strata -n 3 -M 1. The output was then filtered for only reads that contained
a T > C transversion using custom scripts (available upon request). Bedtools
(Quinlan and Hall, 2010) was used to divide the reads into those that were
exonic or intronic.
RNA Preparation and RNA-Seq Analysis
RNA was extracted from cell culture samples using TRIzol (Thermo Fisher
Scientific, 15596-026) and RNeasy Mini Kits (QIAGEN, 74104). Total RNA for(12%) comprise a smaller fraction. In contrast with humans, however, exon
are conserved—a striking difference when compared to humans, where 45%
s (which are normally repressed in undifferentiated cells) to the mouse genome
in mouse brain (Figure 4).
Figure 5. PTBP1 and PTBP2 Regulate Conserved Neuronal Exons
and Nonconserved Cryptic Exons by Titrating the Level of CU-
Repeat-Associated Repression
A proposed model to merge the dual roles of PTBP1 and PTBP2 in neuronal
differentiation and cryptic exon repression. Initially, levels of PTBP1 are high in
undifferentiated cells. During neuronal differentiation, PTBP1 expression de-
creases and PTBP2 is increased. However, while the increase in PTBP2
expression is sufficient to repress nonconserved cryptic exons, it is insufficient
to repress conserved neuronal exons. Thus, in mature neurons, total repres-
sion levels are reduced to activate exons that are important for neuronal dif-
ferentiation, but not reduced enough to allow the incorporation of deleterious
nonconserved cryptic exons.
Figure 6. Conserved versus Nonconserved Axis of the Splicing
Landscape
In the exon definitionmodel of RNA splicing, conserved exons are governed by
splicing factors that can act as enhancers or repressors, depending on context.
Many splicing factors bind to loosely defined consensus sequences, allowing
for the wide diversity in exonic sequences. However, this flexibility comes at a
cost, since cryptic ‘‘exon-like’’ sequences may stochastically appear within
introns—a consequence of mutations that accumulate over evolutionary
timescales. Certain microsatellite-binding splicing factors appear to serve as
cryptic exon repressors, although their original functions prior to the evolution
of higher-order RNA splicing remain unclear. Interestingly, while TDP-43 ap-
pears to primarily regulate nonconserved cryptic exons, PTBP1 and PTBP2
have gained additional roles in the regulation of conserved tissue-specific
exons involved in neuronal maturation and cellular differentiation. Other
splicing factors such as NOVA have been previously documented to regulate
cryptic exons (Eom et al., 2013), although it remains to be seen whether NOVA
regulates nonconserved splicing events. It is predicted that additional cryptic
exon repressors exist to bind repetitive sequences beyond [CU]n and [UG]n.RNA-seq was then processed using the TruSeq Stranded Total RNA Library
Prep Kit (Illumina) to construct 100-bp paired end stranded RNA-seq libraries.
Sample libraries were then sequenced on a HiSeq 2500. Samples were then
de-multiplexed and converted into fastq files.
Fastq files were aligned to mouse and human genomes using HISAT2
(Kim et al., 2015), and gene abundances were calculated using Cufflinks
(Trapnell et al., 2012). To identify cryptic exons, HISAT2-generated BAM
files were processed using StringTie (Pertea et al., 2015), a transcript as-
sembly software. StringTie GTF outputs were then processed for unanno-
tated exons identified in the PTBP1/2 knockdown datasets. Relative read
coverage and splice junction coverage between control and knockdown
conditions were then calculated for each unannotated exon using Cuf-
flinks and SpliceMap (Au et al., 2010) and ranked by fold change accord-
ingly. Data were then displayed on the UCSC Genome Browser to visu-
alize RNA-seq coverage, and each unannotated exon was manually
curated for the presence of CU repeats, vertebrate conservation, and
cryptic exon classification. Vertebrate conservation was determined using
the ‘‘100 vertebrates Basewise Conservation by PhyloP’’ conservation
track; positive likelihood ratio values were considered as conserved
and negative values as nonconserved. Low-quality alignments or mis-
alignments, highly repetitive intergenic regions, intra-exonic splice junc-
tions, and other false positives were manually discarded. Data visualiza-
tion on the Integrative Genomics Viewer (IGV) genome browser was also
used to ensure that cryptic exon alignments were strand-matched to the
associated transcripts.
Antibodies
The following antibodies were used in this study: rabbit polyclonal against
PTBP1 (1:1,000; Cell Signaling, 8776), rabbit polyclonal against PTBP2
(1:500; Proteintech, 55186-1-AP), mouse monoclonal against GAPDH(1:10,000; Sigma-Aldrich, G8795), and rabbit monoclonal against GAPDH
(1:10,000; Cell Signaling, D16H11).
Protein Biochemistry
To obtain homogenate from treated cell cultures, cells were lysed and homog-
enized in RIPA buffer (Sigma-Aldrich) containing protease inhibitor (Roche).
Cell debris and nuclei were removed by centrifugation at 3,200 rpm for
10 min, resulting in supernatant S1 (soluble fraction) and pellet P1 (membrane
associated fraction). Protein concentration of S1 was determined by bicincho-
ninic acid assay (BCA). 20 mg protein was loaded onto 4%–12% (w/v) SDS
polyacrylamide gels. Separated proteins were blotted onto polyvinylidene
fluoride (PVDF) membranes (Whatman) and blocked with 5% (w/v) BSA/
0.01% (v/v) Tween 20 in Tris-buffered saline (TBS) for 1 hr. After blocking,
membranes were incubated overnight at 4C in blocking solution containing
primary antibody. Blots were washed and incubated with the appropriate
horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 hr at
room temperature. Proteins were visualized and quantified using an AFP imag-
ing mini-medical system (AFP Imaging Corporation).
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